{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:21:14Z","timestamp":1771579274196,"version":"3.50.1"},"reference-count":37,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OPTH"],"DOI":"10.2147\/opth.s563499","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:55:12Z","timestamp":1771577712000},"page":"1-13","source":"Crossref","is-referenced-by-count":0,"title":["Reversal of Pharmacologic Mydriasis in Pediatric Subjects with Ryzumvi (0.75% Phentolamine Ophthalmic Solution): A Post-Hoc Pooled Analysis from Three Randomized, Placebo-Controlled Phase 3 Trials"],"prefix":"10.2147","volume":"Volume 20","author":[{"given":"Jay","family":"Pepose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Brigell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-1088","authenticated-orcid":true,"given":"Konstantinos","family":"Charizanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"ref1","unstructured":"Centers for Disease Control and Prevention. Why eye exams are important. Available from: https:\/\/www.cdc.gov\/vision-health\/about-eye-disorders\/why-eye-exams-are-important.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/visionhealth\/resources\/features\/keep-eye-on-vision-health.html. Accessed June 14, 2024."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"435606","DOI":"10.1155\/2015\/435606","volume":"2015","author":"Wilson","year":"2015","journal-title":"J Ophthalmol"},{"key":"ref3","author":"Steiner","year":"2013","journal-title":"Rev Optometric Business"},{"key":"ref4","unstructured":"American Optometric Association. Evidence-based clinical practice guideline: comprehensive pediatric eye and vision examination. American Optometric Association; 2017."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ophtha.2010.06.038","volume":"118","author":"Fozailoff","year":"2011","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2128\u20132134e2121","DOI":"10.1016\/j.ophtha.2009.04.034","volume":"116","author":"Friedman","year":"2009","journal-title":"Ophthalmology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.ophtha.2013.06.039","volume":"120","author":"Wen","year":"2013","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00006324-200401000-00003","volume":"81","author":"Kemper","year":"2004","journal-title":"Optom Vis Sci"},{"key":"ref9","unstructured":"American Optometric Association. School-aged vision: 6 to 18 years of age. Available from: https:\/\/www.aoa.org\/healthy-eyes\/eye-health-for-life\/school-aged-vision?sso=y. Accessed June 26, 2024."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/OPTO.S217645","volume":"12","author":"Major","year":"2020","journal-title":"Clin Optom"},{"key":"ref11","unstructured":"American Academy of Ophthalmology. Eye screening for children. Available from: https:\/\/www.aao.org\/eye-health\/tips-prevention\/children-eye-screening. Accessed June 14, 2024."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"739\u2013746,746e731","DOI":"10.1016\/j.ophtha.2008.12.030","volume":"116","author":"Giordano","year":"2009","journal-title":"Ophthalmology"},{"key":"ref13","first-page":"266","volume":"67","author":"Parisi","year":"1996","journal-title":"J Am Optom Assoc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4155\/tde-2021-0011","volume":"12","author":"Wirta","year":"2021","journal-title":"Ther Deliv"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/0300-1652.184065","volume":"57","author":"Sani","year":"2016","journal-title":"Niger Med J"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Multi-ethnic Pediatric Eye Disease Study G. Prevalence of amblyopia and strabismus in African American and hispanic children ages 6 to 72 months the multi-ethnic pediatric eye disease study. Ophthalmology. 2008;115(7):1229\u20131236e1221. doi:10.1016\/j.ophtha.2007.08.001","DOI":"10.1016\/j.ophtha.2007.08.001"},{"key":"ref17","first-page":"P222","volume":"130","author":"Hutchinson","year":"2023","journal-title":"Pediatric Eye Eval Preferred Pract Pattern Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/OPX.0000000000002226","volume":"102","author":"Bist","year":"2025","journal-title":"Optom Vis Sci"},{"key":"ref19","volume-title":"StatPearls","year":"2020"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/bjo.87.11.1387","volume":"87","author":"Wood","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"ref21","unstructured":"Bausch + Lomb. Tropicamide ophthalmic solution, USP. 2019. Available from: https:\/\/pi.bausch.com\/globalassets\/pdf\/PackageInserts\/Pharma\/Rx-Generics\/Tropicamide-package-insert.pdf. Accessed June 20, 2024."},{"key":"ref22","unstructured":"Akorn. Phenylephrine hydrochloride ophthalmic solution, USP. 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203510s002lbl.pdf. Accessed June 20, 2024."},{"key":"ref23","unstructured":"Akorn. PAREMYD-hydroxyamphetamine hydrobromide, tropicamide solution Akorn. 1992. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=da8a8a19-ac1b-4160-aac4-c4c57598eb5d. Accessed June 20, 2024."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1444-0938.1996.tb04976.x","volume":"79","author":"Siderov","year":"1996","journal-title":"Clin Exp Optom"},{"key":"ref25","volume-title":"StatPearls [Internet]","year":"2024"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1097\/MS9.0000000000002058","volume":"86","author":"Azhar","year":"2024","journal-title":"Ann Med Surg Lond"},{"key":"ref27","volume-title":"StatPearls [Internet]","year":"2024"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ajo.2004.11.010","volume":"139","author":"Pepose","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1518\/0018720024494775","volume":"44","author":"Theeuwes","year":"2002","journal-title":"Hum Fact"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1167\/iovs.06-0759","volume":"48","author":"Franssen","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ophtha.2024.09.010","volume":"132","author":"Pepose","year":"2025","journal-title":"Ophthalmology"},{"key":"ref32","unstructured":"RO Staff. New drug to hasten reversal of mydriasis after dilated exam. Review of Optometry. 2023. https:\/\/www.reviewofoptometry.com\/news\/article\/new-drug-to-hasten-reversal-of-mydriasis-after-dilated-exam. Accessed February 7, 2026."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1167\/iovs.13-12319","volume":"54","author":"Kardon","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref34","unstructured":"MedDRA. Introductory guide MedDRA version 25.0. 2022. Available from: https:\/\/alt.meddra.org\/files_acrobat\/intguide_25_0_English.pdf. Accessed June 18, 2024."},{"key":"ref35","unstructured":"Novocol Pharmaceutical of Canada, Inc. OraVerse\u2122 (phentolamine mesylate) Injection. Novocol. 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/022159s011lbl.pdf. Accessed June 21, 2024."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12663-011-0318-6","volume":"11","author":"Prasanna","year":"2012","journal-title":"J Maxillofac Oral Surg"},{"key":"ref37","unstructured":"Ocuphire Pharma, Inc. Oyster point pharma, Inc. RYZUMVI\u2122 (phentolamine ophthalmic solution) 0.75%, for topical ophthalmic use. Available from: https:\/\/www.ryzumvi.com\/files\/prescribing-information.pdf. Accessed June 21, 2024."}],"container-title":["Clinical Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/112272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/112272","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:55:16Z","timestamp":1771577716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/reversal-of-pharmacologic-mydriasis-in-pediatric-subjects-with-ryzumvi-peer-reviewed-fulltext-article-OPTH"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"URL":"https:\/\/doi.org\/10.2147\/opth.s563499","relation":{},"ISSN":["1177-5483"],"issn-type":[{"value":"1177-5483","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}